3 Biotech Stocks on the Rise News ad
Despite the overall strength of the economy, 2024 was a challenging year for the biotech industry. High borrowing costs – especially ahead of the Fed’s first rate cut in years in September – coupled with the changing landscape in the health care sector have dampened the outlook for many companies. As a result, the benchmark … Read more
